Waning treatment for immune deficiency is a warning for all ‘one-and-done’ therapies
MOLLY FERGUSON FOR STAT
With companies promoting the idea of “one-and-done” gene therapies — and setting prices accordingly — patient advocates hope companies will be more wary.


No hay comentarios:
Publicar un comentario